Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen W. Wright is active.

Publication


Featured researches published by Stephen W. Wright.


Tetrahedron Letters | 1992

Benzyl and t-butyl sulfoxides as sulfenyl halide equivalents: a convenient preparation of benzisothiazolones

Stephen W. Wright; Matthew Mark Abelman; Lori L. Bostrom; Ronald L. Corbett

Abstract A new methodology is described for the synthesis of benzisothiazolones from benzylsulfinyl or t-buthylsulfinyl substituted carboxamides that provides a mild alternative to conventional cyclization methods that employ halogens.


Tetrahedron Letters | 1993

A synthesis of 2-aryl-3-hydroxybenzothiophenes and analogs by the base promoted cyclization of N-phenyl-2-(benzylthio)benzamides

Stephen W. Wright; Ronald L. Corbett

Abstract A new methodology is described for the synthesis of 3-hydroxybenzothiophenes, 3-hydroxypyridothiophenes, and the corresponding selenophene analogs by the base promoted cyclization of corresponding 2-(benzylthio)arenecarboxanilides. The starting materials are readily prepared using directed metalation of the corresponding arenecarboxanilides.


Bioorganic & Medicinal Chemistry | 1995

Metabolism resistant isothiazolone inhibitors of cartilage breakdown

Stephen W. Wright; Joseph J. Petraitis; Douglas G. Batt; Ronald L. Corbett; Susan V. Di Meo; Bruce Freimark; John V. Giannaras; Michael J. Orwat; Donald J. P. Pinto; Michael A. Pratta; Susan R. Sherk; Herman F. Stampfli; Jean M. Williams; Ronald L. Magolda; Elizabeth C. Arner

A series of 2-(arylmethyl)pyridoisothiazolones is reported that inhibit the IL-1 beta induced breakdown of bovine nasal septum cartilage in an organ culture assay. The synthesis and preliminary SAR of these compounds are described. These compounds represent a novel, non-peptide lead series approach to the mediation of the chronic cartilage breakdown associated with arthritic disease. These compounds are relatively resistant to reductive metabolism by liver microsomal preparations and appear to inhibit cartilage breakdown by interfering with the proteolytic activation of matrix metalloproteinases.


Bioorganic & Medicinal Chemistry | 1996

2,5-Diarylisothiazolone: novel inhibitors of cytokine-induced cartilage destruction

Stephen W. Wright; Joseph J. Petraitis; Bruce Freimark; John V. Giannaras; Michael A. Pratta; Susan R. Sherk; Jean M. Williams; Ronald L. Magolda; Elizabeth C. Arner

A series of 2,5-diarylisothiazolones is reported that inhibit the IL-1 beta-induced breakdown of bovine nasal septum cartilage in an organ culture assay. The synthesis and preliminary SAR of these compounds are described. These compounds represent a novel, nonpeptide lead series approach to the mediation of the chronic cartilage breakdown associated with arthritic disease. These compounds are relatively resistant to reductive metabolism by liver microsomal preparations and appear to inhibit cartilage breakdown by interfering with the proteolytic activation of matrix metalloproteinases.


Bioorganic & Medicinal Chemistry Letters | 1993

Inhibition of cartilage breakdown by isothiazolones

Stephen W. Wright; Joseph J. Petraitis; Matthew Mark Abelman; Lori L. Bostrom; Ronald L. Corbett; Alicia M. Green; Rachel M. Kindt; Susan R. Sherk; Ronald L. Magolda

Abstract Isothiazolones and isoselenazolones have been found to inhibit IL-1β induced breakdown of bovine nasal cartilage in an organ culture assay. The synthesis and preliminary SAR of these compounds are described. These compounds represent a novel, non-peptide lead series approach to the mediation of the chronic cartilage breakdown associated with arthritic disease.


Bioorganic & Medicinal Chemistry Letters | 1992

Episulfide inhibitors of lipoxygenase

Stephen W. Wright; Mark J. Nelson

Abstract A set of epoxide and episulfide substrate mimics were synthesized as inhibitors of soybean lipoxygenase. Enzyme inhibition was observed exclusively with the 12,13-episulfides (1a and 4a), with a high degree of regio- and chemoselectivity. Inhibition by 1a was shown to occur with reduction of the enzyme active site iron from the catalytically active Fe(III) to the inactive Fe(II).


Bioorganic & Medicinal Chemistry Letters | 1992

Vinylogous hydroxamic acids: 5-lipoxygenase inhibitors

Stephen W. Wright; Donald J. P. Pinto; Susan R. Sherk; Alicia M. Green; Ronald L. Magolda

Abstract Vinylogous hydroxamic acids were prepared as inhibitors of 5-lipoxygenase. The synthesis and preliminary SAR of these relatively unexplored compounds are described. These compounds are potent 5-lipoxygenase inhibitors which do not inhibit other enzymes of the arachidonic acid cascade.


Journal of Medicinal Chemistry | 1992

Synthesis, chemical, and biological properties of vinylogous hydroxamic acids: dual inhibitors of 5-lipoxygenase and IL-1 biosynthesis

Stephen W. Wright; Richard R. Harris; Janet S. Kerr; Alicia M. Green; Donald J. P. Pinto; Elaine M. Bruin; Robert J. Collins; Roberta L. Dorow; Lisa R. Mantegna


Archive | 1990

Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors

Ronald L. Magolda; Stephen W. Wright


Archive | 1991

Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity

Douglas G. Batt; Stephen W. Wright

Researchain Logo
Decentralizing Knowledge